CDKN2A deletion	B Acute Lymphoblastic Leukemia	CDKN2A deletion	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
CDKN2A deletion	Mantle Cell Lymphoma	CDKN2A deletion	Mantle Cell Lymphoma	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
CDKN2A deletion	Acute Lymphocytic Leukemia	CDKN2A deletion	Acute Lymphocytic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
CDKN2A deletion	Melanoma	CDKN2A deletion	Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDKN2A deletion	Gallbladder Cancer	CDKN2A deletion	Gallbladder Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
CDKN2A deletion	Glioma	CDKN2A deletion	Glioma	vincristine + lomustine + procarbazine hydrochloride Resistant: C3 – Early Trials vincristine + lomustine + procarbazine hydrochloride Resistant : C3	vincristine + lomustine + procarbazine hydrochloride Resistant: C3 – Early Trials vincristine + lomustine + procarbazine hydrochloride Resistant : C3
CDKN2A deletion	Hepatocellular Cancer	CDKN2A deletion	Hepatocellular Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CDKN2A deletion	Melanoma	CDKN2A deletion	Melanoma	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
CDKN2A deletion	Pancreatic Cancer	CDKN2A deletion	Pancreatic Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
CDKN2A deletion	Gastric Adenocarcinoma	CDKN2A deletion	Gastric Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CDKN2A deletion	Diffuse Large B Cell Lymphoma	CDKN2A deletion	Diffuse Large B Cell Lymphoma	T-lymphocyte cell therapy Resistant: C3 – Early Trials T-lymphocyte cell therapy Resistant : C3	T-lymphocyte cell therapy Resistant: C3 – Early Trials T-lymphocyte cell therapy Resistant : C3
CDKN2A deletion	Prolymphocytic Leukemia	CDKN2A deletion	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4

CDKN2A deletion

Associations